Work

The Benefit-to-Risk Balance of Combining Infliximab With Azathioprine Varies With Age: A Markov Model

Year: 2014

Type: article

Source: Clinical Gastroenterology and Hepatology

DOI: 10.1016/j.cgh.2014.07.058

Authors: Frank I. Scott, Ravy K. Vajravelu, Meenakshi Bewtra, Ronac Mamtani, Dale Lee, David S. Goldberg, James D. Lewis

Institutions: University of Pennsylvania, Children's Hospital of Philadelphia

Language: English

Topic: Inflammatory Bowel Disease

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: National Institutes of Health, National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases

Awards: Dietary Patterns and the Course of Inflammatory Bowel Disease, G225780874, Microvascular disease, statins, ACE-inhibitors and post-operative SBO, Training Program in Gastrointestinal Sciences, G4464589005, G62843750, G830265429, Risk and Risk Preferences for Surgery and Medical Therapy in Ulcerative Colitis, Physician Scientist Training in Clinical Oncology

OpenAlex ID: W2035481305

FWCI: 3.168

Cites: 44

Cited by: 39

Related to: 10